ACCORD AVEC AMDIPHARM POUR TRANSACT LAT® | Bourse Reflex
Accueil > Actualités > Communiqués

ACCORD AVEC AMDIPHARM POUR TRANSACT LAT®

Lundi 13 Jul 2009 à 12:51

Milan, le 13 juillet 2009 - Recordati annonce la signature d'un accord avec Amdipharm, groupe pharmaceutique international dont le siège est au Royaume-Uni, pour le marketing et la vente en Italie et au Portugal de TransAct LAT® (local action transcutaneous), un patch transdermique contenant 40 mg de flurbiprofène indiqué pour le traitement symptomatique de douleurs locales liées au système musculosquelettique. Ce produit est déjà sur le marché italien et portugais et les ventes annuelles s'élèvent à environ 13 millions d'euros.

TransAct LAT® is an original system for the administration of flurbiprofen, a well known and widely prescribed non steroidal anti-inflammatory drug (NSAID), which improves its tolerability profile. Recordati has an established franchise in pain and inflammation management and the addition of this product provides a valid further choice for the medical practitioner.

Amdipharm is an International pharmaceutical company. Recognised for its young, dynamic and entrepreneurial image, Amdipharm has garnered a significant level of growth and success since its inception in 2002 and is now widely considered a partner of choice with respect to both the acquisition and management of established brands. Already the company boasts a portfolio of over 60 products which generate sales in over 100 countries. Sales in 2009 are projected to exceed E185 million.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, isin IT 0003828271),with a total staff of over 2,900, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of over 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2008 was E 689.6 million, operating income was E 144.7 million and net income was E 100.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: inver@recordati.it

Media Relations

Claudio Rossetti (Echo Comunicazione d'Impresa)

(39)02 62694736

e-mail: crossetti@echocom.it

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

Copyright Hugin

Ce communiqué de presse est diffusé par Hugin. L'émetteur est seul responsable du contenu de ce communiqué.

[CN#155948]

Partager sur Facebook
Article Précédent :
GROUPE BNP Mise à disposition du...
Article Suivant :
Contrat de liquidité - bilan...

Ecrire un commentaire

J'accepte la charte et que mon commentaire soit publié sur BourseReflex.com 

Les autres actualités


Retour vers 'Communiqués' »




Mots-clés : Euros   Amdipharm   Lat  

Si vous passez un ordre de bourse sur le CAC40 le vendredi soir à 18h, quand sera t-il éxécuté?